OT antagonist 3
OT antagonist 3 is an oxytocin (OT) antagonist extracted from patent WO2007017752A1.
Product Specifications
CAS Number
925703-75-9
UNSPSC
12352005
Target
Oxytocin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology
Assay Protocol
https://www.medchemexpress.com/OT_antagonist_3.html
Solubility
10 mM in DMSO
Smiles
CC1=NN=C(C2=CN=C(OC3=CC=CC(C)=C3C)C=N2)N1C4=CC=C(OC)N=C4
Molecular Formula
C21H20N6O2
Molecular Weight
388.42
References & Citations
[1]Alan Daniel Brown, et al. Substituted triazole derivatives as oxytocin antagonists. WO2007017752A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
134783-Biotin 100 µL
TRNT1 (CCA tRNA Nucleotidyltransferase 1, Mitochondrial, CCA1, Mitochondrial tRNA Nucleotidyl Transferase, CCA-adding, mt CCA-adding Enzyme, MtCCA, mt tRNA CCA-diphosphorylase, mt tRNA CCA-pyrophosphorylase, mt tRNA Adenylyltransferase, CGI-47) (Biotin)
Sign In for Pricing
View Details 
138146-ML750 100 µL
MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-associated Epithelial Membrane Antigen, EMA, Tumor-associated Mucin, CD227, PUM) (MaxLight 750) discontinued
Sign In for Pricing
View Details FA108369-01 500 µg
Anthranilyl-HIV Protease Substrate V trifluoroacetate salt
Sign In for Pricing
View Details FA108369-02 1000 µg
Anthranilyl-HIV Protease Substrate V trifluoroacetate salt
Sign In for Pricing
View Details FA108369-03 2000 µg
Anthranilyl-HIV Protease Substrate V trifluoroacetate salt
Sign In for Pricing
View Details FA108369-04 5000 μg
Anthranilyl-HIV Protease Substrate V trifluoroacetate salt
Sign In for Pricing
View Details